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Outcomes following endovascular abdominal
aortic aneurysm repair (EVAR): An anatomic and
device-specific analysis
Thomas A. Abbruzzese, MD, Christopher J. Kwolek, MD, David C. Brewster, MD, Thomas K. Chung,
MS, Jeanwan Kang, MD, Mark F. Conrad, MD, Glenn M. LaMuraglia, MD, and Richard P. Cambria,
MD, Boston, Mass
Objective: We performed a device-specific comparison of long-term outcomes following endovascular abdominal aortic
aneurysm repair (EVAR) to determine the effect(s) of device type on early and late clinical outcomes. In addition, the
impact of performing EVAR both within and outside of specific instructions for use (IFU) for each device was examined.
Methods: Between January 8, 1999 and December 31, 2005, 565 patients underwent EVAR utilizing one of three
commercially available stent graft devices. Study outcomes included perioperative (<30 days) mortality, intraoperative
technical complications and need for adjunctive procedures, aneurysm rupture, aneurysm-related mortality, conversion to
open repair, reintervention, development and/or resolution of endoleak, device related adverse events (migration,
thrombosis, or kinking), and a combined endpoint of any graft-related adverse event (GRAE). Study outcomes were
correlated by aneurysm morphology that was within or outside of the recommended device IFU. 2 and Kaplan Meier
methods were used for analysis.
Results: Grafts implanted included 177 Cook Zenith (CZ, 31%), 111 Gore Excluder (GE, 20%), and 277 Medtronic
AneuRx (MA, 49%); 39.3% of grafts were placed outside of at least one IFU parameter. Mean follow-up was 30  21
months and was shorter for CZ (20 months CZ vs 35 and 31 months for GE and MA, respectively; P < .001). Overall
actuarial 5-year freedom from aneurysm-related death, reintervention, and GRAE was similar among devices. CZ had a
lower number of graft migration events (0 CZ vs 1 GE and 9 MA); however, there was no difference between devices on
actuarial analysis. Combined GRAE was lowest for CZ (29% CZ, 35% GE, and 43% MA; P  .01). Graft placement
outside of IFU was associated with similar 5-year freedom from aneurysm-related death, migration, and reintervention
(P > .05), but a lower freedom from GRAE (74% outside IFU vs 86% within IFU; P  .021), likely related to a higher
incidence of graft thrombosis (2.3% outside IFU vs 0.3% within IFU; P  .026). The differences in outcome for grafts
placed within vs outside IFU were not device-specific.
Conclusion: EVAR performed with three commercially available devices provided similar clinically relevant outcomes at 5
years, although no graft migration occurred with a suprarenal fixation device. As anticipated, application outside of
anatomically specific IFU variables had an incremental negative effect on late results, indicating that adherence to such
IFU guidelines is appropriate clinical practice. ( J Vasc Surg 2008;48:19-28.)Since its first introduction by Parodi in 1991,1 endo-
vascular repair of abdominal aortic aneurysms (EVAR) has
been validated in a number of large single center reports
and randomized clinical trials.2-9 There is no longer debate
about the early benefits of EVAR, including shorter hospi-
tal stays, less blood loss, shorter operating times, and lower
early morbidity and mortality.4,5-8 Recent studies have
focused on late outcomes, including the need for reinter-
ventions.2,10-12 Despite reports to the contrary from the
EVAR 2 trial participants,8 the intuitively logical applica-
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multicenter reports.13,14
As experience with EVAR has increased, this modal-
ity has been offered to a wider population of patients,
and our experience has confirmed favorable late out-
comes;2 accordingly, some 70% of abdominal aortic an-
eurysm repairs at our institution are currently performed
with EVAR. Concomitant with the increased EVAR
utilization has been the availability of a variety of graft
designs and configurations. This technical evolution has
allowed the endovascular surgeon to choose from several
devices, without guidelines, or specific criteria as to
which device may be preferred in any given clinical/
anatomic situation. The only device-specific guidelines
available relate to the suggested anatomic constraints
and device-sizing table located in each device’s instruc-
tion for use (IFU). Furthermore, few studies address the
effect of device type and anatomic selection criteria on
late outcomes.15-21
Accordingly, in this study, we performed an anatomi-
cally stratified (ie, within vs outside of device-specific IFU),
device specific analysis, of our EVAR experience to deter-
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outcomes.
METHODS
We performed a retrospective review of patients under-
going EVAR for elective, primary repair of infrarenal ab-
dominal aortic aneurysm from January 8, 1999 to Decem-
ber 31, 2005 at the Massachusetts General Hospital
(MGH). EVAR performed for repair of thoracic aortic
aneurysms, isolated iliac artery aneurysms, subclavian artery
aneurysms, vascular trauma, anastomotic pseudoaneu-
rysms, or other vascular pathologies were excluded. The
initial time interval was chosen to correspond with the first
implantation of a currently commercially available en-
dograft at our institution, and the later date was chosen to
ensure that patients under consideration had at least 2 years
of follow-up.
We limited this analysis of the MGH EVAR experience
to endograft devices that remain commercially available and
in active use. These devices are generally characterized by
a bifurcated, modular, fully supported design with low-
profile features, and many of them have undergone
several iterations of graft construction and delivery sys-
tem design features over the study interval. First gener-
ation devices, defined as those that were used early in our
experience, which have subsequently been withdrawn
from commercial use were excluded from consideration
in this study. Furthermore, to ensure adequate numbers
of patients in each stent graft group for comparison, we
limited the current study to the three most frequently
used stent graft devices at MGH, these included the
Cook Zenith (Cook Incorporated, Bloomington, Ind),
Gore Excluder (W. L. Gore & Associates, Incorporated,
Flagstaff, Ariz) and Medtronic AnueRx (Medtronic Vas-
cular, Santa Rosa, Calif) devices.
The primary operating surgeon was responsible for all
decisions regarding treatment selection (EVAR vs open
repair) and personally performing device planning mea-
surements and selections. Patient and device selection,
device deployment strategy, and procedure performance
were as previously described.2 All patients underwent
follow-up by contrast-enhanced computed tomography
(CT) scans either at discharge or within 1 month, 6
months, 12 months, and then yearly evaluations thereafter.
Aneurysm morphology (neck diameter, neck length,
neck angle, aneurysm sac angle, and maximum sac diame-
ter) was measured retrospectively by the primary author
(TAA) for the purposes of the study using the original axial
CT images and three-dimensional reconstructions. Neck
angle was defined as the angle between the suprarenal aorta
to neck of the aneurysm. Aneurysm sac angle was defined as
the angle between the neck of the aneurysm and the aneu-
rysm sac. Since the study was designed to compare device-
specific outcomes after successful device deployment, we
limited the analysis to successful EVAR procedures in
which a device was successfully deployed. Preoperative iliac
anatomy was not considered.Study outcomes included perioperative (30 days)
mortality, intraoperative technical factors and adjunctive
procedures, aneurysm rupture, aneurysm-related mortality,
conversion to open repair, reintervention, development
and/or resolution of endoleak, device related adverse
events (migration, thrombosis or kinking), and a combined
endpoint of any graft-related adverse event (GRAE). Intra-
operative technical factors included caudal migration dur-
ing graft deployment (requiring placement of a proximal
cuff for adequate fixation), development of a type 1 or 3
endoleak, or access site complications; all of which gener-
ally led to adjunctive corrective procedures. Intraoperative
adjunctive procedures were procedures performed outside
of the original device deployment strategy that were em-
ployed to address unexpected intraoperative technical is-
sues. Aneurysm-related mortality (ARM) was defined as
death from any cause within 30 days of the primary EVAR
procedure, death within 30 days of any secondary reinter-
vention or surgical complication, or any death due to
aneurysm rupture or device-related complication. Signifi-
cant device migration was defined as migration 5 mm
compared with the initial position of the graft and device
kinking was defined as a flow-limiting acute angulation of
the graft or graft limb(s) that generally required a corrective
intervention (eg, angioplasty and/or stenting of the graft
body or limb). GRAE was defined as a combination of all
aneurysm and EVAR-related events including perioperative
mortality, aneurysm-related mortality, need for unplanned
intraoperative adjunctive procedure, late graft problem
(migration5 mm, kinking, or thrombosis), conversion to
open repair, aneurysm rupture, and the late development of
a type 1, 3 or 4 endoleak.
Study outcomes were stratified by aneurysm morphol-
ogy that was either within or outside of specific device
instructions for use (IFU). The specific IFU parameters
used for this study are listed in Table I.
Descriptive statistics are reported as mean  standard
deviation. Comparisons between groups were performed
using a two-tailed t test for continuous variables and 2 test
for categorical data. Time-based clinical outcomes were
evaluated using Kaplan-Meier life-table analysis. The log-
rank test was used to compare Kaplan-Meier curves and
logistic regression was used to identify variables potentially
associated with study endpoints. In all analyses, a P value
.05 was used to determine statistical significance.
RESULTS
Patient demographics, clinical characteristics, and
aneurysm morphology
Over the study interval, 585 patients underwent EVAR
at MGH. Of these, 565 patients met the study inclusion
criteria and comprise the study group. These patients un-
derwent primary EVAR for infrarenal AAA using 177 Cook
Zenith (CZ, 31.3%), 111 Gore Excluder (GE, 19.6%)
and 277 Medtronic AneuRx (MA, 49.0%) devices. Mean
follow-up was 29.6 20.8 months and was shorter for the
CZ group than the other device groups (19.7  14.5
ded in
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and MA, respectively; P  .001).
Patient demographics and clinical characteristics are
summarized in Table II. Mean patient age was 76.2  7.5
years with a range of 44 to 99 years and was not different
between groups. Male patients comprised 80% of the study
group. More female patients received a GE device com-
pared with the other devices (34.2% GE vs 14.7% CZ and
17.7% MA, respectively; P  .001). Coronary disease was
present in 50.8% of patients, including 10.3% with a history
of previous myocardial infarction, 20.2% with angina, and
Table I. Stent graft device instructions for use (IFU) anat
Stent graft device IFU
IFU parameter C
Neck diameter 18 m
Neck length 15 m
Neck angulation (suprarenal aorta to neck) 45 d
Aneurysm sac angulation (neck to aneurysm sac) 60 d
Iliac fixation length 10 m
Aortic oversizing 15%
Iliac oversizing 1 mm
Iliac diameter 7.5 m
Device-specific parameters of aneurysm morphology and graft sizing, inclu
analysis to determine IFU status and device-specific effects.
Table II. Patient demographics and clinical characteristics
Patient characteristic Cook Zenith n  177 Gore
Age (y) 76.0  7.8 75
Gender
Male 85.3%
Female 14.7%
CVA 9.6%
HTN 71.8%
Hypercholesterolemia 55.9%
Diabetes mellitus 11.9%
Coronary diseasea 54.2%
Renal insufficiencyb 14.1%
Dialysis-dependent 3.4%
Smoking history
Previous smoker 61.0%
Current smoker 12.4%
COPD 22.0%
Steroid-dependent 4.0%
Home O2 1.1%
PVD 7.3%
Preoperative aneurysm morphology
Sac diameter 58.4  11.1 mm 54
Neck diameter 24.1  2.8 mm 22
Neck length 23.4  11.5 mm 25
Neck angle 24.2  19.8° 24
Sac angle 42.0  19.5° 42
CVA, Cerebrovascular accident; HTN, hypertension; COPD, chronic obstr
aCoronary disease defined as having a history of any of the following:
revascularization (percutaneous or surgical), angina, or cardiac valvular dise
bRenal insufficiency defined as serum creatinine 2.0 g/dL.14.4% with atrial fibrillation. Significant chronic obstruc-tive pulmonary disease was present in 23.2% of patients,
25% of whom were steroid-dependent. Similarly, chronic
renal insufficiency (serum creatinine concentration 2.0
g/dL) was present in 12.6% of patients and 1.6% of patients
were on hemodialysis. There was no difference in comor-
bidities between groups.
Preoperative CT data was available for measurement in
529 of 565 (93.6%) study patients. Mean maximum aneu-
rysm sac diameter was 56.1  11.3 mm with a range of 40
mm to 112 mm and was larger in the CZ group than the
other groups (58.4  11.1 mm CZ vs 54.3  8.7 mm GE
and graft sizing parameters
neurysm morphology
Graft brand
enith Gore Excluder Medtronic AneuRx
28 mm 26 mm 26 mm
15 mm 15 mm
s 60 degrees 45 degrees
s Not specified Not specified
10 mm 25 mm
2 mm 2 mm
1 mm 1 mm
20 mm 18.5 mm 18 mm
each device’s instructions for use. These parameters were used in the IFU
der n  111 Medtronic AneuRx n  277 P
7.5 76.6  7.2 .50
.8% 82.3% <.001
.2% 17.7% <.001
.9% 12.3% .67
.4% 73.3% .74
.2% 45.3% .04
.7% 13.0% .91
.0% 50.9% .31
.4% 14.1% .09
.9% 0.7% .07
.5% 56.0% .55
.7% 13.7% .12
.0% 21.3% .17
.5% 7.6% .27
.9% 2.2% .56
.5% 11.3% .14
8.7 mm 55.3  12.1 mm .003
2.5 mm 23.2  2.6 mm <0.001
11.9 mm 25.3  12.2 mm 0.25
22.1° 21.0  19.8° 0.19
20.5° 37.4  21.6° 0.04
pulmonary disease; PVD, peripheral vascular disease.
hmia, myocardial infarction, congestive heart failure, previous coronaryomic
for a
ook Z
m or
m
egree
egree
m
m orExclu
.7 
65
34
10
69
43
11
45
6
0
59
20
30
5
0
14
.3 
.8 
.2 
.7 
.6 
uctive
arrhyt
ase.and 55.3  12.1 mm MA, respectively; P  .003). Mean
n IFU
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mm and was larger in the CZ group than the other groups
(24.1 2.8 mmCZ vs 22.8 2.5 mmGE and 23.2 2.6
mm MA, respectively; P  .001). Mean neck length was
24.6  11.9 mm and was not different between groups
(P  .25). Mean neck angulation was 22.7  20.8° with a
range of 0° to 88° and did not vary between groups (P 
.19). Mean aneurysm sac angulation was 39.9 20.8° and
was less in the MA group than the other two groups
(37.4  21.6° MA vs 42.0  19.5° CZ and 42.6  20.5°
GE, respectively; P  .04).
Overall, 222 of 565 (39.3%) endografts were per-
formed outside of at least one device-specific IFU parame-
ter as detailed in Table III. Endograft placement outside of
IFU occurred more frequently in the CZ group than the
other two groups (50.8% CZ grafts vs 39.4% GE and 39.7%
MA grafts, respectively; P  .001).
Operative and perioperative outcomes
Intraoperative technical factors and adjunctive pro-
cedures. A variety of difficulties were encountered during
the placement of endografts in this series. Intraoperative
problems involved issues of proximal or distal fixation
resulting in type 1 endoleak or caudal migration of the graft
during deployment, limb kinking or thrombosis, and issues
related to access vessels. Overall, we performed 180 adjunc-
tive procedures in 145 of 565 (25.6%) patients. Intraoper-
ative problems encountered included proximal type 1 en-
doleak in 72 (12.7%) patients, distal type 1 endoleak in 18
(3.2%) patients, type 3 endoleak in 8 (1.4%) patients, caudal
migration of the graft during deployment in 13 (2.3%),
graft limb kinking in 20 (3.5%) patients, acute graft limb
thrombosis in 2 (0.4%) patients, incomplete opening of the
contralateral gate in 4 (0.7%) patients, access vessel compli-
cations in 6 (1.1%) patients, and rupture in 2 (0.4%) pa-
tients. The incidence of intraoperative problems was not
different between groups.
Intraoperative adjunctive procedures included 82 an-
gioplasties, 40 proximal graft extensions, 13 bare metal
stents placed at the proximal fixation point, 12 bare metal
Table III. IFU parameter violations in patients outside de
violations across the study cohort)
IFU parameter Overall outside IFU (n  565) Cook Zenith (n
Neck diameter 7.1% (40/565) 6.2% (11/1
Neck length 15.4% (87/565) 20.9% (37/1
Neck angulation 10.3% (58/565) 13.0% (23/1
Sac angulation 14.7% (26/177)* 14.7% (26/1
Aortic oversizing 17.0% (96/565) 10.2% (18/1
Number of IFU parameter violations per patient
0 60.7% (343/565) 51.4% (91/1
1 27.4% (155/565) 35.6% (63/1
2 8.7% (49/565) 9.6% (17/1
3 or more 3.2% (18/565) 3.4% (6/17
IFU, Instructions for use.
*Cook Zenith is the only device that includes aneurysm sac angulation as astents placed at a distal attachment point or the site ofkinking, 5 aortouniiliac conversions with femoral-femoral
bypass, 3 iliofemoral bypasses, 2 limb thrombectomies, 1
femoral-femoral bypass graft, and 2 renal artery stents.
Notably, 31 patients required two or more procedures to
address the intraoperative problem. Technical success, de-
fined as successful endograft placement with resolution of
the intraoperative issue, was achieved in 132 of 145
(91.0%) patients. The incidence of adjunctive procedures
did not differ between device groups (20.5% CZ, 24.5%
GE, and 25.4% MA, respectively; P  .48).
Perioperative mortality. Perioperative death, those
within 30 days of the index operation, occurred in 10 of
565 patients (1.8%). They included 2 patients who experi-
enced iliac artery avulsion during graft placement (one of
whom died intraoperatively, and the other died in the
postoperative period from a necrotizing soft tissue infec-
tion), 2 patients died from complications related to early
graft limb thrombosis and acute leg ischemia, 1 patient died
from complications of open conversion, 2 patients suffered
hemispheric strokes, 1 patient had a myocardial infarction
complicated by cardiogenic shock, and 2 patients died from
sudden, unexplained cardiovascular collapse. Perioperative
mortality did not differ between groups (1.1% CZ, 1.8%
GE, and 2.2% MA, respectively; P .72). Notably 4 of 10
deaths occurred in patients who were outside of IFU (1
patient outside IFU in both neck length and angulation, 1
patient outside IFU in neck and sac angulation, 1 patient
outside IFU in neck length, and 1 patient outside IFU in
neck angulation).
Late outcomes
Aneurysm rupture. Aneurysm rupture occurred in six
of 565 patients (1.1%) during the study interval. Rupture
occurred at an average of 14.9 months postoperation with
a range from 1.2 to 60.4 months. Five of the six patients
(83%) died either of the rupture itself or subsequent com-
plications thereof. One patient, who presented a new type 3
endoleak at the junction of the main body and contralateral
limb that resulted in acute sac expansion and rupture, was
successfully treated by percutaneous endovascular interven-
specific IFU (The incidence and distribution of IFU
) Gore Excluder (n  111) Medtronic AneuRx (n  277) P
3.6% (4/111) 9.0% (25/277) .147
12.6% (14/111) 13.0% (36/277) .051
6.3% (7/111) 10.1% (28/277) .189
N/A N/A N/A
17.1% (19/111) 21.3% (59/277) .009
69.4% (77/111) 63.2% (175/277) .043
23.4% (26/111) 23.8% (66/277)
5.4% (6/111) 9.4% (26/277)
1.8% (2/111) 3.6% (10/277)
criteria.vice-
 177
77)
77)
77)
77)
77)
77)
77)
77)
7)tion consisting of bridging the contralateral limb/main
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patients ruptured from sac expansion with persistent type 2
endoleaks and were treated by open conversion during
which the aneurysm sacs were opened, and bleeding lum-
bar arteries were suture ligated. One patient developed
rupture in the perioperative period and underwent conver-
sion to open repair, but ultimately died after a complicated,
protracted hospital course. Two patients died prior to
intervention, one of whom refused intervention. In all, four
out of six rupture events (67%) occurred in patients with a
known endoleak (one type 1 endoleak and three type 2
endoleaks). The incidence of post-EVAR rupture was not
different between groups (1.7% CZ, 0.0% GE, and 1.1%
MA, respectively; P  .40).
As depicted in Fig 1, by Kaplan-Meier analysis, freedom
from aneurysm rupture at 1 and 5 years was 98% for CZ,
100% for GE, and 99% for MA. There was no difference in
freedom from aneurysm rupture between device groups
(P .149 CZ vs GE, P .377 CZ vsMA and P .252 GE
vs MA).
All-cause mortality. By Kaplan-Meier analysis, over-
all survival at 1 year and 5 years was 94% and 61%, respec-
tively. At 1 year, survival was 95% for CZ, 95% for GE, and
93% for MA; and at 5 years, survival was 82% for CZ, 64%
Fig 1. Kaplan-Meier freedom from aneurysm rupture; P  .149
CZ vs GE, P  .377 CZ vs MA, and P  .252 GE vs MA.for GE, and 56% for MA. Mortality was higher in the MAgroup than the CZ group (P .049), but was not different
between CZ and GE (P  .52) or GE and MA (P  .41).
Aneurysm-related mortality. Aneurysm-related mor-
tality (ARM) occurred in 14 of 565 patients (2.5%) and was
not significantly different between device groups (1.1%CZ,
1.8% GE, and 3.6% MA, respectively; P  .22). Aneurysm
rupture accounted for 3 of 14 deaths (21.4%), iliac artery
avulsion/rupture during endograft placement resulted in 2
deaths (14.3%), graft limb thrombosis with limb ischemia
for 2 deaths (14.3%), conversion to open aneurysm repair
for 1 death, colon ischemia for 1 death (7.1%), stroke for 1
death (7.1%), myocardial infarction for 1 death (7.1%),
acute renal failure for 1 death (7.1%), and unexplained
cardiopulmonary arrest for 2 deaths (14.3%). Overall, eight
of 14 deaths occurred in the perioperative period and two
deaths occurred during the index hospital admission, but
outside of the 30-day perioperative period. Thus, the ma-
jority of ARM (10 of 14 deaths, 71.4%) occurred during
the index hospital admission. Aneurysm rupture accounted
for the majority of late ARM.
By Kaplan-Meier analysis, freedom from aneurysm-
related mortality was 97% at 1 year, 97% at 2 years, 97% at
3 years, 97% at 4 years, and 95% at five years. As depicted in
Fig 2, freedom from aneurysm-related mortality was not
device specific (99% CZ, 98% GE, and 96% MA, respec-
tively; P .15 CZ vs GE, P .66 CZ vs MA, and P .35
Fig 2. Kaplan-Meier freedom from aneurysm-relatedmortality; P
 .15 CZ vs GE, P  .66 CZ vs MA, and P  .35 GE vs MA.GE vs MA).
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open surgical repair was required in 4 of 565 patients
(0.7%) and was not different between groups (0.6% CZ,
1.8% GE, and 0.4% MA, respectively; P  .31). The indi-
cation for conversion to open surgical repair included an-
eurysm rupture in two patients and sac expansion in two
patients. Notably, all conversion events occurred in patients
with type 2 endoleaks emanating from patent lumbar
branches. Aneurysm rupture was treated by endograft ex-
plantation and open aortic reconstruction in one patient
and open ligation of back-bleeding lumbar branches and
aneurysm sac closure without endograft explantation in the
other. Sac expansion was treated with endograft explanta-
tion and open aortic reconstruction in both instances. Both
patients who underwent graft explantation for sac enlarge-
ment and persistent type 2 endoleak had failed multiple
percutaneous procedures intended to address the endoleak.
Perioperative mortality after conversion to open repair was
25%.
Reintervention. Over the study interval, a total of 88
reinterventions were performed on 60 patients, resulting in
an incidence of any reintervention of 10.6%. Indications for
reintervention included type 1 endoleak in 7 patients, type
2 endoleak in 31 patients (2 of whom presented with
aneurysm rupture), type 3 endoleak in 1 patient (who
presented with aneurysm rupture), undefined endoleak in 5
patients, graft limb stenosis or thrombosis in 6 patients, and
significant graft migration in 8 patients (7 of whom devel-
oped aneurysm sac enlargement and 1 who presented with
aneurysm rupture). Overall, 73 of 88 (82.9%) reinterven-
tions were performed percutaneously. Percutaneous proce-
dures included placement of proximal and distal extension
limbs, coil embolization of branch vessels to address en-
doleak, and angioplasty and stenting of graft limb kinks.
Open procedures included open conversion to aneurysm
repair, graft limb thrombectomy, repair of common femo-
ral artery pseudoaneurysms, and extra-anatomic bypass for
limb occlusion. By Kaplan-Meier analysis, freedom from
reintervention (Fig 3) was 95% at 1 year and 80% at 5 years,
and was not device-specific (94% CZ, 98% GE, and 95%
MA, respectively at 1 year; and 91% CZ, 82% GE, and 77%
MA, respectively at 5 years; P .45 for CZ vs MA, P .99
CZ vs GE, and P  .46 GE vs MA). The corrective
procedure was clinically successful in resolving the problem
93% of cases.
Late graft problems (migration, thrombosis, and
kinking). Graft migration, thrombosis and kinking oc-
curred in 22 of 565 (3.9%) patients over the study interval.
Graft migration events are detailed in Table IV. By Kaplan-
Meier analysis, there was no difference in the freedom from
graft migration at either 1 year (100% CZ, 100% GE, 100%
MA) or 5 years (100% CZ, 99% GE, and 92%MA) between
device groups (P .332 CZ vs GE, P.12 CZ vs MA, and
P.13 GE vs MA). There was no difference in either graft
thrombosis (1.7% CZ, 0.0% GE, and 1.1% MA, respec-
tively; P .39) or graft kinking (1.1% CZ, 0.0% GE, and
1.5% MA, respectively; P  .45) between device groups.Graft-related adverse events. By Kaplan-Meier anal-
ysis, there was no difference in the freedom from cumula-
tive graft-related adverse events (GRAE) at either 1 year
(93% CZ, 97% GE, and 93% MA) or 5 years (89% CZ, 82%
GE, and 81% MA) between device groups (P 0.670 for
CZ vs GE, P 0.765 for CZ vs MA, and P .435 for GE
vs MA).
IFU effects on early and late outcomes. A total of 222
of 565 (39.3%) EVAR procedures were performed outside
of at least one device specific IFU parameter. In comparing
the aneurysm morphology of EVAR performed within vs
outside of IFU, we noted that outside of IFU aneurysms
had larger maximum sac diameters (57.3  11.9 mm
outside IFU vs 54.5  9.3 mm within IFU; P  .001),
shorter neck lengths (22.2 11.9 mm outside IFU vs 27.0
 10.7 mm within IFU; P  .001), larger neck diameters
(23.7  2.7 mm outside IFU vs 22.7  2.3 mm within
IFU; P .001), greater neck angulation (29.2  21.8°
outside IFU vs 16.3  15.3° within IFU; P  .001) and
greater sac angulation (46.7 20.7° outside IFU vs 34.6
17.6° within IFU; P  .001). In consideration of gender
and aneurysm morphology, women were outside IFU pa-
rameters more often than men with respect to neck length
(7.1% of females vs 1.3% of males; P  .001) and neck
angulation (3.5% females vs 0.7% males; P  .013). Oper-
ative time was greater for EVAR performed outside IFU
(140.4  49.6 minutes within IFU vs 152.2  72.6
Fig 3. Kaplan-Meier freedom from reintervention; P .45 CZ vs
GE, P  .99 CZ vs MA, and P  .46 GE vs MA.minutes outside IFU; P  .030).
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Patient
Graft
brand
Aneurysm morphology
Graft extent (from lowest
renal or iliac bifurcation)
and component oversizing
Iliac fixation
length Clinical Summary
Maximum
sac
diameter
(mm)
Neck
length
(mm)
Neck
diameter
(mm)
Neck
angle
(°)
Proximal
(mm)
Right
limb
(mm)
Left limb
(mm)
Right
(mm)
Left
(mm)
Within
IFU Presentation Reintervention
1 Excluder 61 30 25 10 IR (5) CI (14) CI (18) 45 42 Yes 5 mm
migration,
no
endoleak
None
OS (3.5) OS (2.5) OS (2.5)
2 AneuRx 57 15 24 4 IR (5) CI (21) CI (34) 28 31 Yes Proximal
type 1
endoleak
Proximal cuff
OS (2) OS (3) OS (4)
3 AneuRx 74 17.5 26 21 IR (2.5) EI (n/a) CI (37) 62 28 Yes Proximal
type 1
endoleak
Proximal cuff
OS (2) OS (1) OS (4)
4 AneuRx 54 10 23 20 IR (2.5) CI (0) CI (5) 25 20 No Proximal
type 1
endoleak
Proximal cuff
OS (1) OS (3) OS (2)
5 AneuRx 46 17 22 22 IR (0) CI (27) CI (20) 40 37.5 Yes 7 mm
migration,
no
endoleak
None
OS (6) OS (5) OS (3)
6 AneuRx 72 22 27 47 IR (0) CI (50) EI (n/a) 42 55 No 5 mm
migration
with sac
growth,
no
endoleak
Proximal cuff
OS (1) OS (2) OS (2)
7 AneuRx 68 42 20 47 IR (2.5) CI (2.5) CI (15) 27.5 27.5 No Proximal
type 1
endoleak,
aneurysm
rupture
Proximal and
distal cuffs
OS (4) OS (4) OS (6)
8 AneuRx 54 30 23 0 IR (0) CI (12) CI (10) 27 26 Yes Proximal
type 1
endoleak
with sac
growth
Proximal cuff
OS (3) OS (3) OS (2)
9 AneuRx 61 25 20 26 IR (5) CI (9) CI (0) 38 35 Yes Migration
into sac,
large
proximal
type 1
endoleak
AUI
conversion
with fem-
fem bypass
OS (4) OS (5) OS (1)
10 AneuRx 54 30 23 0 IR (10) CI (0) CI (0) 45 33 Yes 5 mm
migration,
no
endoleak
None
OS (3) OS (2) OS (3)
IR, Infrarenal aortic fixation (distance from lowest renal artery); CI, common iliac artery fixation (distance from iliac bifurcation); EI, external iliac artery
fixation; OS, component oversizing (millimeters).
JOURNAL OF VASCULAR SURGERY
July 200826 Abbruzzese et alWith respect to clinical outcomes, EVAR procedures
performed outside of IFU had a similar perioperative mor-
tality (1.7% within IFU, 1.8% outside IFU; P1.00), but a
lower freedom from aneurysm-related mortality at 1 year
(100% within IFU, 94% outside IFU) and 5 years (100%
within IFU, 89% outside IFU) (P  .001). Freedom from
reintervention was similar at 1 year (95% within IFU vs 96%
outside IFU) and 5 years (85% within IFU vs 76% outside
IFU) (P  .39). However, as the number of outside IFU
parameters increased, there was an incremental decrease in
the freedom from reintervention at both 1 year (95% within
IFU vs 87% outside 3 IFU parameters) and 5 years (85%
within IFU vs 21% outside 3 IFU parameters) (P  .01).
There was no effect of IFU on the rate of aneurysm rupture
(0.6% within IFU vs 1.8% outside IFU; P  .19), conver-
sion to open surgical repair (0.3% within IFU vs 1.4%
outside IFU; P .20), graft migration (2.1% within IFU vs
1.4% outside IFU; P  .44), or graft kinking (0.6% within
IFU vs 1.8% outside IFU; P  .12). There was a higher
incidence of graft thrombosis outside IFU (2.3% outside
IFU vs 0.3% within IFU; P  .03). By Kaplan-Meier
analysis, there was a lower freedom from any GRAE at 1
year (94%within IFU vs 92% outside IFU) and 5 years (82%
within IFU vs 67% outside IFU) for grafts placed outside
IFU when compared with grafts placed within IFU (P 
.021). When outcomes were correlated to both IFU status
and device type, there were no device-dependent changes
in outcome.
DISCUSSION
Our results indicate that the three commercially avail-
able endograft devices evaluated in this study (Cook Ze-
nith, Gore Excluder, and Medtronic AneuRx), provide
similar clinical outcomes at 5 years. We found no device-
specific differences in perioperative mortality, aneurysm
rupture, aneurysm-related mortality, conversion to open
repair, or reintervention rates. Endografts placed outside of
at least one IFU parameter were associated with higher
perioperative mortality, aneurysm-related mortality, rein-
tervention, graft thrombosis, and combined graft-related
adverse events.
In our series, more women received a GE device (op-
posed to a CZ or MA device), which relates to our prefer-
ential use of the GE device in patients with small iliac
systems. Additionally, women were outside IFU parame-
ters more often than men with respect to neck length and
neck angulation. This gender discrepancy in aneurysm
morphology and device type could bias results of the GE
group in favor of the CZ and MA groups. The effects of
gender on EVAR outcomes have previously been described
in a number of reports. In a review of a prospective database
of 118 MA grafts placed for aneurysm disease, Nordness et
al found that that women had longer operative times,
higher overall complication rates, and a higher 1-month
mortality compared with men.22 Although they demon-
strated higher complication rates in women after EVAR,
only 17 of the 118 procedures were performed in women,
which limits the power of the study to identify predisposingfactors relating female gender to unfavorable outcomes.
Sampaio et al found that women undergoing EVAR tended
to be older, and had smaller iliac arteries that were less
tortuous, but more calcified than men.23 Females had
smaller aneurysms with shorter proximal necks than males,
and EVAR in women was associated with greater need for
additional access maneuvers such as angioplasty, creation of
an iliac “chimney” conduit, and aortouniiliac conversion.
However, despite more complicated anatomy and techni-
cally demanding EVAR procedures, women and men had
similar clinical outcomes at 24months. These findings were
similar to Hugl et al who demonstrated a higher rate of
conversion to open surgical repair in women at 24 months
post-EVAR compared with men, but similar rates of sur-
vival, freedom from aneurysm rupture, and reintervention
rates.24 Biebl and colleagues also showed that women had
shorter, more angulated aneurysm necks and smaller iliac
arteries than men, but found similar rates of perioperative
and late clinical outcomes with the exception of early
wound dehiscence and open surgical conversion within the
first year post-EVAR.25 Our study results support the pre-
vious findings that women tend to have more hostile aneu-
rysm neck anatomy than men, but given the evidence in the
literature, we do not believe that gender discrepancies in
device allocation significantly biased our results.
There were device-specific differences in IFU status
that may have affected results. The CZ group had more
devices placed outside of IFU than the other devices,
specifically related to placement in aneurysms with larger
neck diameters. This difference is attributable to the CZ
device being available with larger main body diameters than
either the GE or MA devices, thus obviating placement in
larger diameter aneurysm necks. The CZ device group also
had a larger maximum aneurysm sac diameter than the
other groups. Preoperative aneurysm sac diameter has been
shown to be an important determinant of long-term out-
come following EVAR,12,26,27 and thus our results could
have been skewed away from the CZ group in favor of the
GE andMA groups; but, in fact, the opposite was observed.
Peppelenbosch et al stratified EVAR outcomes based on
initial maximum aneurysm sac diameter and found that
patients with large aneurysms (6.5 cm or larger) were older
and were at higher operative risk than patients with smaller
aneurysms.12 In their series, patients in the largest aneu-
rysm diameter cohort had twice the perioperative mortality,
a higher rate of early type 1 endoleak, a lower freedom from
aneurysm rupture, and freedom from aneurysm-related
death than patients in the smaller aneurysm cohorts. In a
review of the nationwide EVAR database of Australia,
Boult et al determined that large initial aneurysm size, neck
angulation 45°, and short infrarenal neck were all associ-
ated with increased perioperative complications and need
for reintervention.26 These findings were supported by a
review of 923 patients who were treated in a multicenter
prospective clinical trial by Zarins.27 Patients were stratified
by those who aneurysm was 5.5 cm. He found that
patients with large aneurysms were older, were at higher
operative risk, and had a lower freedom from rupture,
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from conversion to open surgical repair than patients with
smaller aneurysms. Although the results of our series could
have been skewed in favor of the GE and MA groups, the
difference in mean preoperative sac diameter between
groups was small and unlikely to have had a significant
effect on late outcomes.
Suprarenal fixation was associated with a lower cumu-
lative incidence of graft migration. There were 10 signifi-
cant graft migrations in our series, all of which occurred in
devices without suprarenal fixation (GE and MA, respec-
tively). Of the 10 graft migration events, seven occurred in
patients who were within IFU and three occurred in pa-
tients outside IFU. Reinterventions were performed in
seven patients. Although there were no graft migration
events in endografts with suprarenal fixation, there was no
significant difference in freedom from graft migration on
Kaplan-Meier analysis. This discrepancy likely relates to a
combination of a low graft migration event rate and differ-
ences in follow-up between device groups. Graft migration
has been shown to occur with infrarenal fixation and is
thought to relate to aneurysm neck length, aneurysm neck
and device apposition zone length, and distal device sup-
port within the iliac system.28-32 Our findings are consis-
tent with those found in the literature, and indeed our graft
migration rate is low at 2.5% over 5 years (for grafts with
infrarenal fixation), which has been reported in the litera-
ture to range from 2-10%. Proximal and distal fixation are
important variables in inhibiting graft migration, however,
we found no consistent relationship between graft extent
(either proximal or distal) or component oversizing and
graft migration events.
It is intuitively logical that better anatomic results will
be achieved and complications reduced when EVAR is
performed within vs outside of device-specific IFU. In a
series of articles from the EUROSTAR database, the
investigators studied the effects of aneurysm sac and neck
diameter10, neck length16, and neck angulation18 on late
outcomes, although they did not analyze outcomes by
device-specific IFU parameters. Waasdorp et al showed a
higher rates of aneurysm rupture, open conversion and
mortality in patients with a sac diameter 6 cm or neck
diameter 26 mm after 4 years of follow-up.10 Leurs
demonstrated that a neck length 15 mm was associated
with significantly increased rates of early (30 days) and
late proximal type 1 endoleak.16 Similarly, Hobo et al.
found that EVAR in patients with severe aneurysm neck
angulation ( 60°) had higher rates of early proximal type
1 endoleak and graft migration, and greater late proximal
neck dilatation, type 1 endoleak, and reintervention rates.18
In a review of their EVAR experience, Fulton and col-
leagues stratified patients by IFU status with respect to neck
anatomy (length, angulation, and diameter) and found that
patients outside IFU experienced higher rates of graft
migration, device-related complications, and secondary in-
terventions.30 Our data support that placement of en-
dografts outside of device specific IFU parameters is asso-
ciated with higher perioperative and aneurysm-relatedmortality. In our series, we did not detect a difference in
patient demographics or clinical characteristics based on
IFU status, indicating that patients outside IFU simply had
anatomically more complicated aneurysms than those
within IFU and did not represent a higher medical risk
group to account for the mortality differences. Presumably,
the higher rates of reinterventions and graft-related adverse
events that we observed in patients outside IFU contrib-
uted to a higher rate of perioperative and aneurysm-related
mortality.
This retrospective study has important limitations and
the results should be interpreted cautiously. First, the dif-
ference in follow-up intervals for the study groups could
have had profound effects on determining outcome differ-
ences between device groups. The GE and MA groups had
similar mean follow-up (31 and 34 months, respectively),
and the CZ group had significantly shorter follow-up
(20 months). In our series, the CZ group had a shorter
follow-up because this device became commercially avail-
able later than either the GE or MA devices. However,
limiting the analysis to a time interval based on CZ avail-
ability would have reduced the number of subjects in the
GE and MA groups, which could have introduced a signif-
icant selection bias (ie, by comparing third and fourth
generation GE and MA devices with early generation CZ
devices and thereby unfairly favoring the GE and MA
groups), and reduced the power of the study to detect
device-specific differences in outcome.
IFU status was determined based on direct measure-
ment from original CT scan data. The vessel diameter and
length measurements were not based on centerline axial
measurements, as the availability of CT three-dimensional
reconstructions with postimaging processing that provided
for centerline diameter and length measurements evolved
over the study interval. M2S reconstructions were available
for only 40% of the study cohort, thus, the measurements
used for this study were performed directly from the digital
CT image by the primary author without centerline recon-
structions. Although the lack of centerline measurements
may alter the IFU stratification to a degree, all study
measurements were made by a single individual, which
should limit measurement variability and thus minimize
any effect on our conclusions.
The study was also limited to patients in whom a device
had been successfully deployed, so by design, IFU status
was heavily-weighted towards parameters relating to prox-
imal fixation (aneurysm neck length, diameter, and angu-
lation), and not on access issues. Therefore, we cannot
analyze the effect(s) of access-related issues (iliac diameter,
tortuosity and calcification) on clinical outcomes or detect
any device-specific differences thereof.
CONCLUSION
EVAR performed with three commercially available
devices (Cook Zenith, Gore Excluder, and Medtronic An-
euRx) provided similar clinically relevant outcomes at 5
years, although no graft migration occurred in our series
with a suprarenal fixation device. As anticipated, EVAR
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had an incrementally negative effect on late results. Al-
though treatment outside IFU still yielded respectable
results (1.8% perioperative mortality), EVAR under these
circumstances should be performed cautiously, and perhaps
not at all in patients who are otherwise candidates for open
operation.
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